Imaging contrasts and tumor-to-tissue ratios were consistent with the in vivo behavior of other radiolabeled anti-FAP mAbs; contrast and ratios improved as the radiopharmaceutical extravasated from the blood pool and began to localize in target tissues. This evidence concerns the gene FAP and neoplasm.